Pliant Therapeutics Director Robert Iannone Receives 60,000-Share Award

What Happened
Robert Iannone, a director of Pliant Therapeutics (PLRX), was granted a derivative equity award for 60,000 shares on 2026-07-09. The Form 4 reports the grant at $0.00 per share (i.e., no cash paid on grant); the filing lists the transaction as an award/acquisition (code A).

Key Details

• Transaction date: 2026-07-09; Form 4 filed: 2026-07-13 (appears timely).
• Award: 60,000 derivative shares reported at $0.00 per share (transaction type A).
• Vesting: 1/36th of the shares vest and become exercisable on each monthly anniversary of July 9, 2026, subject to continuous service (36-month monthly vesting).
• Shares owned after transaction: Not specified in this Form 4.
• No 10b5-1 plan, tax‑withholding details, or sale/concurrent disposition reported in this filing.

Context
The award is reported as a derivative equity grant with a time‑based monthly vesting schedule — commonly used for restricted stock units or similar retention awards. This filing documents a compensation grant to a director rather than an open‑market buy or sale; such grants are routine for board compensation and do not by themselves indicate a buy/sell signal.